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Inhalation plus intravenous 
colistin versus intravenous 
colistin alone for treatment 
of ventilator associated 
pneumonia
ABSTRACT
In the setting of intensive care units the incidences of multi-drug resistant gram-negative (MDR-GN) pathogens causing 
ventilator associated pneumonia (VAP) has increased, leading clinicians to use colistin. Our aim was to assess outcomes 
associated with the use of inhalation and intravenous colisitn versus only intravenous colistin in patients with MDR-GN VAP. 
A retrospective, single centre study at University Hospital Centre, Zagreb. Patients were divided in two groups, according 
to their administration of antibiotics – inhalation and intravenous (INH+IV) administration for 8 patients or intravenous only 
(IV) administration for 23 patients. 
The results showed that demographic and clinical characteristics and the gram negative pathogens isolated were similar 
between the two groups, except for K. pneumoniae, which was higher in the IV group. No statistically significant differen-
ce between the two groups were observed regarding intensive care unit mortality (P=0.951), sepsis (P=0.474), acute 
respiratory distress syndrome (P=0.548), length of ICU stay (P=0.686) and length of mechanical ventilation (P=0.858). A 
statistically significant difference was found regarding the eradication of pathogens in respiratory cultures (P= 0.018). 
The addition of inhalation to intravenous colistin in MDR-GN VAP improves microbiologic outcome, but does not improve 
ICU mortality in these patients. Larger prospective trials are warranted to confirm the benefit of adjunctive inhalation colistin 
as a MDR-GN VAP therapy in the critically ill.
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Introduction
Ventilator associated pneumonia (VAP) 
is a serious and common complicati-
on for patients in intensive care units 
(ICU) and contributes to mortality. (1-4) 
Gram-negative bacteria, such as Aci-
netobacter baumanni, Pseudomonas 
aeruginosa, and Klebsiella pneumoni-
ae, are frequently associated with VAP 
in the ICU. Unfortunately, the incidence 
of multi-drug resistant gram-negati-
ve (MDR-GN) pathogens is relatively 
high in the ICU setting. The increased 
incidence of MDR-GN pathogens and 
the lack of new effective antimicrobial 
drugs have lead clinicians to employ 
colistin again. Colistin was previously 
removed from use because of nephro- 
and neurotoxicity. (5,6) 
Colistin is a cationic detergent that 
damages bacterial cytoplasmic mem-
brane, which leads to leakage of intra-
celular contents causing death. This 
mechanism of action makes it less sus-
ceptible to bacterial resistance mec-
hanisms. (7) There are promising data 
about the use of inhalation colistin in 
cystic fibrosis patients. (8,9) Currently, 
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there are limited and conflicting data on 
the efficacy and adverse events regar-
ding aerosolized colistin in the treatment 
of VAP in the critically ill. (10,11,12) The 
aim of this study is to compare the effi-
cacy and safety of administering inha-
lation and intravenous colistin versus 
only intravenous colistin in patients with 
MDR-GN VAP.
Materials and methods
This retrospective study was conducted 
at the 13-bed surgical ICU of the Univer-
sity Hospital Centre, Zagreb. Patients 
≥ 18 years of age admitted to the ICU 
between January 2013 and December 
2013 were eligible for evaluation of their 
medical charts. Patients were excluded 
if they had a diagnosis of cystic fibrosis, 
had never received appropriate intra-
venous antibiotics, were mechanically 
ventilated for < 48 hours, and recei-
ved ≤ 72 hours of antibiotic therapy. All 
subjects were enrolled only once. Recor-
ds of subjects treated with inhalation 
and intravenous colistin were compared 
to those who received only intravenous 
colistin. The following baseline charac-
teristics were collected from the medical 
records of eligible patients: age, body 
mass index (BMI), gender, Simplifi-
ed Acute Physiology Score (SAPS) II, 
American society of Anesthesiology 
(ASA) score, comorbid conditions, 
presence of sepsis, acute respiratory 
distress syndrome (ARDS) and neu-
tropenia at the time of bronchoalveolar 
lavage (BAL) or tracheal aspirate (TA). 
Treatment related factors and clinical 
outcomes data, including duration of 
ICU stay, length of mechanical ventila-
tion as well as adverse events to colistin 
therapy were also assessed. Data were 
collected from medical records, as well 
as from pharmacy and microbiology 
databases. Due to the retrospective 
nature of the investigation, consent 
was waived. 
Pneumonia was considered ventilator 
associated pneumonia if the onset 
occurred after the patient was intuba-
ted for ≥ 48 hours and the infection 
was not incubating before the initiation 
of mechanical ventilation (6) and when 
pneumonia was defined on two or 
more serial chest X-rays or CT-scans 
with a suggestive image of pneumonia 
for patients with underlying cardiac or 
pulmonary disease. In patients witho-
ut underlying cardiac or pulmonary 
disease one definitive chest X-ray or 
CT-scan was sufficient. Additionally, at 
least one of the following clinical signs 
or symptoms was required: fever > 
38 °C with no other cause, leukopenia 
(<4,000 WBC/mm3) or leucocytosis 
(≥ 12,000 WBC/mm3); and at least 
one of the following (or at least two 
in cases of clinical pneumonia): new 
onset of purulent sputum or chan-
ge in character of sputum, cough or 
dyspnea or tachypnea, suggestive 
auscultation, or worsening gas exc-
hange. These factors were considered 
in combination with a bacteriologic 
diagnostic performed by: broncho-
alveolar lavage (BAL) with a threshold 
of > 104 Colony Forming Units (CFU)/
ml or ≥ 5 % of BAL obtained cells con-
taining intracellular bacteria on a direct 
microscopic exam (classified on the 
diagnostic category BAL), protected 
brush (PB Wimberley) with a thres-
hold of >103 CFU/ml, distal protected 
aspirate (DPA) with a threshold of > 
103 CFU/ml, quantitative culture of 
Lower Respiratory Tract (LRT) speci-
men (e.g. endotracheal aspirate) with 
a threshold of 106 CFU/ml. (13) The 
primary endpoint of this study was the 
clinical - ICU mortality. The secondary 
endpoints were the microbiological 
outcome - the negativisation of blood 
and respiratory cultures, and the occu-
rrence of adverse events during coli-
stin treatment. Adverse events during 
colistin treatment such as nephrotoxi-
city, neurotoxicity, bronchoconstricti-
on were recorded. Nephrotoxicity was 
defined as a decline in renal function 
prompting renal replacement therapy, 
as a reduction in the calculated creati-
nine clearance of 50% from the baseli-
ne, as failure according to Risk, Injury, 
Failure, Loss, and End-stage kidney 
disease (RIFLE) criteria. (14)
Microbiological testing
Antimicrobial susceptibility testing and 
interpretation was performed for thera-
peutically relevant antibiotics on Mue-
ller-Hinton agar using the standard 
disk diffusion method according to the 
European Committee on Antimicro-
bial Susceptibility Testing (EUCAST) 
guidelines. (15) Minimum inhibitory 
concentration (MIC) was determined 
for all isolates to imipenem, merope-
nem, and colistin. MICs were interpre-
ted using the criteria established by 
EUCAST. (15)
Treatment regimen
The daily dose of intravenous coli-
stin was 9 million international units 
divided into three doses in patients 
with normal renal function, and a daily 
dose of additional inhalational coli-
stin was 4 million international units 
divided into two doses. The nebulizer 
was positioned in the inspiratory limb 
of the ventilator circuit. The ventilator 
system used at the University Hospital 
Centre during the course of this study 
was Puritan Bennett. Humidification 
was discontinued during delivery of 
the aerosol, and suctioning through 
the endotracheal tube was avoided 
following the administration of inha-
lation.
Statistical analysis
All interval variables followed a nor-
mal distribution (according to the 
Shapiro-Wilkov test) and are presen-
ted descriptively as mean values and 
standard deviations, and differences 
between groups were tested by the 
Student’s t-test. Variables that use 
ordinal and nominal scales are shown 
as the frequency and the differences 
between groups were tested by the 
Mann-Whitney U-test (ASA score) or 
chi-square test. Data analysis was 
done in STATISTICA version 12 (Stat-
Soft, OK, USA). All p values below 0.05 
were considered statistically signifi-
cant.
Results 
During the study period 31 patients 
were treated with colistin for MDR VAP. 
Among them 8 patients simultaneously 
received inhalation and intravenous 
colisitn (INH+IV), and 23 received intra-
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venous colistin (IV) alone or in combi-
nation with another antimicrobial agent. 
There were no statistically significant 
differences in baseline characteristi-
cs between the two groups (Table 1). 
The most common MDR-GN patho-
gens identified included P.aeruginosa, 
A.baumanni and there were no dif-
ferences between the two groups. 
K.pneumoniae was identified only in 
the IV group (21.8%, P=0.014). Some 
patients also had extrapulmonary MDR-
GN infections including blood, urine, 
and soft/skin tissue, and there were no 
differences between the two groups. 
Complications including sepsis and 
ARDS were similar between the two 
groups. In the INH+IV group one pati-
ent (12.5%) was presented with renal 
dysfunction, while in the IV group four 
patients (17.4%) were presented with 
renal dysfunction (P=0.746). Adverse 
events, such as neurotoxicity, was not 
recorded, while bronchoconstriciton 
developed in 1/8 patients in the INH+IV 
group. The mean duration of colistin 
therapy was comparable between the 
two treatment groups: 10.3±5.72 for the 
INH+IV group and 16.9±15.10 for the 
IV group (P=0.240). In the two groups 
the duration of mechanical ventilation 
(25.1±13.68 vs. 23.9±17.91, P=0.858) 
and the ICU length of stay (30.5±11.56 




Age (years) 72.4±11.87 72.5±12.91 0.984*
BMI (kg/m2) 24.0±7.59 27.9±7.96 0.230*
Female sex (N, % ) 3 (37.5%) 9 (39.1%) 0.935**
Clinical score

















Diabetes 1 (12.5%) 8 (34.8%) 0.231**
COPD 1 (12.5%) 5 (21.8%) 0.568**
Malignancy 1 (12.5%) 4 (17.4%) 0.746**
Renal failure 4 (50.0%) 10 (43.5%) 0.749**
Microbiology
(N, %)
A. baumanii 5 (62.5%) 12 (52.2%) 0.613**
P. aeruginosa 7 (87.5%) 19 (82.6%) 0.746**




5 (62.5%) 8 (34.8%) 0.171**
Complications
(N, %)
Sepsis 5 (62.5%) 11 (47.8%) 0.474**
Septic shock 3 (37.5%) 12 (52.2%) 0.474**
ARDS 0 (0.0%) 1 (4.4%) 0.548**
Neutropenia 1 (12.5%) 2 (8.7%) 0.754**
Nephrotoxicity 1 (12.5%) 4 (17.4%) 0.568**
Neurotoxicity 0 (0.0%) 0 (0.0%) -
Bronhoconstriction 1 (12.5%) 0 (0.0%) 0.085**
(days)
Duration of colistin therapy 10.3±5.72 16.9±15.10 0.240*
Mechanical ventilation 25.1±13.68 23.9±17.91 0.858*
ICU stay 30.5±11.56 33.8±21.88 0.686*
Clinical outcome(N, 
%)
ICU mortality 6 (75.0%) 17 (73.9%) 0.951**
Microbiologic 
outcome(N, %)
Negativisation of respiratory 
cultures
5 (62.5%) 3 (14.3%) 0.018**
ARDS-acute respiratory distress syndrome; ASA- American Society of Anesthesiology; BMI-body mass index; COPD-chronic 
obstructive pulmonary disease; ICU-intensive care unit; INH+IV- inhalation + intravenous colistin; IV-intravenous colistin; SAPS 
II- Simplified Acute Physiology Score 
* Student t-test; ** chi-square test; † Mann-Whitney U-test; 
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vs.33.8±21.88, P=0.686) were not 
statistically significantly different. The 
patients receiving colistin INH+IV had 
better microbiological outcomes - the 
negativisation of respiratory cultures 
(5/8, 62.5%) compared to patients in 
the IV group (3/21, 14.3%, P= 0.018). 
ICU mortality was similar between the 
two groups (75% vs 73.9%, P=0.951) 
(table 1).  
Discussion
The present study demonstrated that 
the addition of INH to IV colistin in pati-
ents with MDR-GN VAP did not provi-
de any additional theapeutic benefit it 
terms of ICU mortality, but provided a 
benefit in microbiological outcome – 
that is, the negativisation of respiratory 
cultures. In addition, adverse events 
as nephrotoxicity were comparable 
in both groups. Neurotoxicity was not 
observed, and bronchoconstriction 
was only observed in the INH+IV 
group. Pseudomonas aeruginosa was 
the most common pathogen, followed 
by Acinetobacter baumannii and Kle-
bsiella pneumoniae isolated only in 
the IV group.
In theory, direct delivery of an antibiotic 
to the site of the infection should be 
beneficial and might lower systemic 
adverse effects. In some studies of 
inhalation colistin added to the IV has 
shown promising results. (10, 16, 17) 
However, the results from studies inclu-
ding a control group are not consistent. 
Korbila et al. demonstrated a better 
outcome of VAP in patients treated with 
colistin inhalation than with IV colistin. 
(12) By contrast, other studies showed 
no additional benefit. (11,18) The study 
of Korbila et al. failed to demonstrate 
mortality differences between the gro-
ups. (12) Data from the present study 
also failed to demonstrate differences 
in mortality, but showed that adding 
aerosolized colistin to IV improves 
microbiological outcome - the negativi-
sation of respiratory cultures. The lack 
of statistical significance for mortality 
may be due to several factors, including 
a relatively small sample size.
With regard to adverse events, the inci-
dences of nephrotoxicity observed, the 
main limiting factor for colistin use in the 
past was found to be comparable with 
recent reports. (10, 19, 20) Furthermore 
bronchoconstriction was reported in 
one patient, which is in line with the 
study by Kwa et al. (21)
There are several important limitati-
ons of our study that should be noted. 
Inhaled colistin was administered via 
conventional nebulizers, which do not 
control the particle size, and therefore 
the question of the actual amount of 
the drug being delivered to the lungs 
remains. The study was performed at 
a single centre and the results may not 
be generalised to other centers. Furt-
hermore, the retrospective and obser-
vational nature of this study limits our 
ability to establish causality between 
the use of inhalation antibiotic therapy 
and ICU survival. 
Conclusion
In conclusion, the present study demon-
strated a better outcome in negativisati-
on of respiratory cultures when inhaled 
colistin was used in combination with 
intravenous colistin (INH+IV) compa-
red to IV colistin alone. Well-designed 
randomized controlled trials are nee-
ded to verify the additional benefits of 
inhaled colistin in the ICU setting.
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